Brief: Palisade Bio Streamlines Operations And Identifies Capital Efficiencies To Focus All Resources On Advancement Of Lead Clinical Program, Lb1148
15/09/2022 13:40
Sept 15 (Reuters) - Palisade Bio Inc PALI.O :
* PALISADE BIO STREAMLINES OPERATIONS AND IDENTIFIES CAPITAL
EFFICIENCIES TO FOCUS ALL RESOURCES ON ADVANCEMENT OF LEAD
CLINICAL PROGRAM, LB1148
* PALISADE BIO - IDENTIFIED EFFICIENCIES, TOOK COST-SAVING
MEASURES OF OVER $1.5 MILLION PER ANNUM TO STREAMLINE BUSINESS,
INCLUDING 20% REDUCTION IN WORKFORCE
Source text for Eikon: ID:nGNX2JG3S1
Further company coverage: PALI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing